Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

12 evidence topics · 12 sources

Distant-stage five-year relative survival, all metastatic prostate cancer
SEER measureQuoted value
Distant-stage five-year relative survival“40.1%”